Visit https://www.peervoice.com/GPC860 to view the entire programme with slides. After completing “Could PSMA Be the ‘Bulls-Eye’ Target in mCRPC?”, participants will be able to: Describe the mechanism of the prostate-specific membrane antigen (PSMA) theranostic approach in metastatic castration-resistant prostate cancer (mCRPC); Recall the clinical trials for the development of PSMA radioligand therapy in mCRPC; Identify which patients may be considered candidates for 177Lu-PSMA-617 therapy.